Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

62P - Proteomic and single-cell landscape reveals novel pathogenic mechanisms of HBV-infected intrahepatic cholangiocarcinoma


10 Sep 2022


Poster session 13


Tumour Site

Hepatobiliary Cancers


Xu Shuaishuai


Annals of Oncology (2022) 33 (suppl_7): S19-S26. 10.1016/annonc/annonc1036


X. Shuaishuai, W. Wu, R. Chen, C. Ye, Q. Li, J. Chen, Q. Jiang, J. Ruan

Author affiliations

  • Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, 310003 - Hangzhou/CN

Abstract 62P


Despite the epidemiological association between intrahepatic cholangiocarcinoma (ICC) and hepatitis B virus (HBV) infection, little is known about the relevant oncogenic effects. Therefore, we sought to identify the genomic, proteomic and single cell transcriptomic architecture of HBV-infected ICC tumors.


A cohort of 32 HBV-infected ICC and 89 non-HBV-ICC were characterized using whole-exome sequencing, proteomic analysis, and single cell RNA sequencing.


Proteomic analysis revealed decreased cell-cell junction levels in HBV-ICC patients. The cell-cell junction level had an inverse relationship with EMT program in ICC patients. Analysis of the immune landscape found that more CD8 T cells and Th2 cells were present in HBV-ICC patients. Single cell analysis indicated that TGFβ-signaling related EMT program changes increased in tumor cells of HBV-ICC patients. And ICAM1+ TAMs are correlated with a poor prognosis and contribute to the EMT in HBV-ICC patients. Immune checkpoints analysis indicated the immunosuppressive landscape of CD8 T cells in HBV-ICC patients.


Our findings provide new insights into the behavior of HBV-infected ICC driven by various pathogenic mechanisms involving decreased cell junction levels and increased progression of the EMT program. Our analysis of the immunosuppressive landscape provides mechanistic information useful for the design of efficacious immune-oncology treatments in intrahepatic cholangiocarcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


1.National Natural Science Foundation of China; 2.Natural Science Foundation of Zhejiang Province; 3.\"Hundred Talents Plan (Clinical Medicine)\" Foundation of Zhejiang University.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.